Patents Assigned to CANTAB BIOPHARMACEUTICALS PATENTS LIMITED
  • Pharmaceutical formulations of PEGylated liposomes and blood coagulation factors
    Patent number: 11484499
    Abstract: The present invention provides a pharmaceutical composition for subcutaneous administration comprising a blood factor and a colloidal particle comprising about 0.5 to 20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer, wherein the blood factor is not encapsulated in said colloidal particle.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: November 1, 2022
    Assignee: Cantab Biopharmaceuticals Patents Limited
    Inventor: William Henry
  • Optimised subcutaneous therapeutic agents
    Patent number: 11351112
    Abstract: Methods and dosage formulations are provided for subcutaneous administration in which therapeutic agents are modified to increase the hydrophilicity and molecular dimensions in relation to the native state of the therapeutic agent, in which the Cmax:Caverage ratio is lower than the Cmax:Caverage ratio of the agent when delivered intravenously.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: June 7, 2022
    Assignee: Cantab Biopharmaceuticals Patents Limited
    Inventors: William Henry, Richard Wolf-Garraway, John Charles Mayo, Michael James Earl
  • Pharmaceutical Formulations of PEGylated Liposomes and Blood Coagulation Factors
    Publication number: 20190060235
    Abstract: The present invention provides a pharmaceutical composition for subcutaneous administration comprising a blood factor and a colloidal particle comprising about 0.5 to 20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer, wherein the blood factor is not encapsulated in said colloidal particle.
    Type: Application
    Filed: August 1, 2018
    Publication date: February 28, 2019
    Applicants: Cantab Biopharmaceuticals Patents Limited, Cantab Biopharmaceuticals Patents Limited
    Inventor: William HENRY
  • OPTIMISED SUBCUTANEOUS THERAPEUTIC AGENTS
    Publication number: 20180036229
    Abstract: Methods and dosage formulations are provided for subcutaneous administration in which therapeutic agents are modified to increase the hydrophilicity and molecular dimensions in relation to the native state of the therapeutic agent, in which the Cmax:Caverage ratio is lower than the Cmax:Caverage ratio of the agent when delivered intravenously.
    Type: Application
    Filed: August 30, 2017
    Publication date: February 8, 2018
    Applicant: Cantab Biopharmaceuticals Patents Limited
    Inventors: William HENRY, Richard WOLF-GARRAWAY, John Charles MAYO, Michael James EARL
  • Pharmaceutical Formulations of PEGylated Liposomes and Blood Coagulation Factors
    Publication number: 20170304203
    Abstract: The present invention provides a pharmaceutical composition for subcutaneous administration comprising a blood factor and a colloidal particle comprising about 0.5 to 20 mole percent of an amphipathic lipid derivatized with a biocompatible hydrophilic polymer, wherein the blood factor is not encapsulated in said colloidal particle.
    Type: Application
    Filed: October 6, 2015
    Publication date: October 26, 2017
    Applicant: Cantab Biopharmaceuticals Patents Limited
    Inventor: William HENRY
  • OPTIMISED SUBCUTANEOUS THERAPEUTIC AGENTS
    Publication number: 20150086524
    Abstract: Methods and dosage formulations are provided for subcutaneous administration in which therapeutic agents are modified to increase the hydrophilicity and molecular dimensions in relation to the native state of the therapeutic agent, in which the Cmax:Caverage ratio is lower than the Cmax:Caverage ratio of the agent when delivered intravenously.
    Type: Application
    Filed: April 16, 2013
    Publication date: March 26, 2015
    Applicant: CANTAB BIOPHARMACEUTICALS PATENTS LIMITED
    Inventors: William Henry, Richard Wolf-Garraway, John Charles Mayo, Michael James Earl
  • CONJUGATED BLOOD COAGULATION FACTOR VIII
    Publication number: 20130150302
    Abstract: The present invention provides a biocompatible polymer conjugated to FVIII via one or more cysteine residues, suitably via a linker across a reduced disulphide bond in FVIII, and pharmaceutical compositions comprising such conjugated forms of FVIII.
    Type: Application
    Filed: April 28, 2011
    Publication date: June 13, 2013
    Applicant: CANTAB BIOPHARMACEUTICALS PATENTS LIMITED
    Inventor: William Henry
  • CONJUGATED BLOOD COAGULATION FACTOR VIIA
    Publication number: 20130129698
    Abstract: The present invention provides a biocompatible polymer conjugated to FVIIa via one or more cysteine residues, suitably via a linker across a reduced disulphide bond in FVIIa, and pharmaceutical compositions comprising such conjugated forms of FVIIa.
    Type: Application
    Filed: April 28, 2011
    Publication date: May 23, 2013
    Applicants: POLYTHERICS LIMITED, CANTAB BIOPHARMACEUTICALS PATENTS LIMITED
    Inventor: William Henry